Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencingtm on Platinum® at US HUPO Conference
Quantum-Si Incorporated (NASDAQ: QSI):
WHAT: The Protein Sequencing Companytm, Quantum-Si Incorporated, will showcase its Next-Generation Protein Sequencingtm instrument, Platinum®, and recent enhancements at the 20th Anniversary US HUPO Conference in Portland, Oregon on March 9-13. Additionally, researchers will present data from Platinum and highlight how protein sequencing on the benchtop instrument is providing deeper insights into proteins through streamlined workflows.
WHY: Quantum-Si brings the groundbreaking power of single-molecule proteomics with the first-to-market Next-Generation Protein Sequencertm, the Platinum instrument, to every lab, everywhere.
WHO AND WHEN:
Justyna Fert-Bober, Ph.D., Assistant Professor, Dept of Cardiology, Smidt Heart Institute, Cedars Sinai and Kenneth Skinner, Ph.D., Quantum-Si Staff Scientist, present the Breakfast Seminar: Joining Forces: Next-Generation Protein Sequencingtm and Mass Spectrometry to Power PTM Analysis
Get the latest updates on applications and workflows and discover the power of using Kinetic Signatures to sequence proteins and detect changes in the proteome, including PTM analysis.
Wednesday, March 13 | 7:15-8:15a.m. PT
Dr. Fert-Bober, Ph.D. will also participate in the panel discussion, Post-Translational Modifications to Proteoforms
Learn how the Fert-Bober lab at Cedars Sinai distinguished citrullinated arginine from non-citrullinated arginine using Quantum-Si's Platinum.
Tuesday, March 12 | Parallel Session 7
Poster Presentations:
Kendrick Nguyen, Ph.D., Quantum-Si Product Application Specialist presents: Quantum-Si's Next-Generation Protein Sequencertm Enables Protein Detection and Peptide Characterization
Poster Number: P01.13
Monday, March 11 | 1:30-3:00p.m. PT
Edgar Manriquez-Sandoval of Johns Hopkins University presents: Enzymatic Addition of C-Terminal Azides to Polypeptides for Single-Molecule Sequencing
Poster Number: P515
Monday, March 11 | 1:30-3:00pm PT
Additionally, Quantum-Si will showcase Platinum's groundbreaking technology at Booth #315 during US HUPO exhibition hours on March 10, 11, and 12.
WHERE: The 2024 US HUPO Conference is being held at the Hyatt Regency Portland, 375 NE Holladay St, Portland, OR 97232
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Companytm, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
Invitation to attend Vitrolife AB (publ) conference call regarding presentation of the interim report Q2, 2024. The presentation will be held in English.
Time: Wednesday 17 July, 2024 at 10.00 a.m. CET.
To attend the conference call, please use this...
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...
Neuromod Devices Ltd. (Neuromod), the global medical technology business that created the first and only FDA Approved tinnitus treatment device, Lenire, has today announced the appointment of Tom Maher as General Counsel, effective July 5, 2024....
The "Annual GMP Master Class 2024" training has been added to ResearchAndMarkets.com's offering.
cGMPs or Current Good Manufacturing Practices is a general encompassing term for the regulations that the control of all facets of life sciences...
The Canadian Dermatology Association (CDA) is proud to announce this year's recipients of its Member Awards and Public Education Awards, following a detailed review of nominations received by the Membership and Awards Committee using a thorough...
IntelGenx Corp. (the "Company" or "IntelGenx" a subsidiary of IntelGenx Technologies Corp.) , has successfully completed the BUENA Alzheimer's disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the...